Pulmonary Drugs Market is Expected to Witness Massive Growth as AstraZeneca enters into Partnership with Propeller Health to add Smart Features to its Symbicort Inhaler for the Treatment of COPD
Chronic obstructive pulmonary disease (COPD) or also known as chronic obstructive respiratory disease is a progressive condition wherein the airways become swollen, inflamed, and clogged due to the buildup of mucus. This mucus becomes the first line of defense against any irritant which leads to difficulty in breathing, coughing, chest pain, wheezing, and shortness of breath. With time, this mucous thickens and makes it difficult for the air to pass through. Increasing incidence of respiratory diseases is expected to drive growth of the global pulmonary drugs market . According to the Centers for Disease Control Prevention (CDC), over 25 million U.S. citizens have asthma. According to the same source, in 2017, around 1 in children had asthma. Moreover, according to the World Health Organization (WHO), in 2016, around 251 million cases of chronic pulmonary obstructive disease (COPD) were reported globally. Such a massive increase in respiratory diseases has i...